WEREWOLF THERAPEUTICS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $18.80 million for the 12-month period ending 2025-12-31, per its S-4 filed 2026-09-22.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $4.60M.
- WEREWOLF THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was -$16.30M, a 213.99% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2021 was $14.30M, a 113.43% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2020 was $6.70M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $18.80M S-4 · filed 2026-09-22 | |
| 2024-12-31 | $20.70M S-4 · filed 2026-09-22 | |
| 2023-12-31 | $4.60M 10-K · filed 2025-03-11 | |
| 2022-12-31 | -$16.30M 10-K · filed 2024-03-07 | $16.30M 10-K · filed 2023-03-23 |
| 2021-12-31 | $14.30M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $6.70M 10-K · filed 2022-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |